CNS Pharma

CNS Pharma

Early Stage

Breakthrough technologies for central nervous system cancers.

Breakthrough technologies for central nervous system cancers.


Raised this Round: Raised: $628,558

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type


SEC Filing Type

RegCF    Open SEC Filing

Year Founded



Healthcare & Pharmaceuticals

Tech Sector


Houston, Texas

Glioblastoma Multiforme (GBM) is one of the deadliest forms of brain cancer -- and CNS Pharma wants to do something about it. They’re in the midst of developing Berubicin, a breakthrough drug whose clinical trials have yielded promising results. Berubicin was created at MD Anderson Cancer Center, and it’s the first of its class of drugs to cross the blood brain barrier and reach cancer cells in brain tumor patients. It’s also been granted Orphan Drug status by the US FDA, and CNS expects to start its Phase 2(a) clinical trial soon. CNS has also entered into a collaboration agreement with Reata Pharmaceuticals and plans to list on the NASDAQ in 2018.
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
CNS Pharma on Republic
Platform: Republic
Security Type: SAFE

Follow company

Follow CNS Pharma on Republic

Buy CNS Pharma's Deal Report

Warning: according to the close date for this deal, CNS Pharma may no longer be accepting investments.

CNS Pharma Deal Report

Get KingsCrowd’s comprehensive report on CNS Pharma including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether CNS Pharma is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the CNS Pharma deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge